Market Newsdesk

Cranbury, NJ, Nov. 24, 2020 (GLOBE NEWSWIRE) — Infragistics, the leader in UI/UX and business intelligence solutions powering the world’s largest enterprise software applications, has partnered with Editor & Publisher magazine, the authoritative voice of news publishing, to bring a real-time view of daily COVID-19 death and infection rates across 223 countries to news publishers. Infragistics’ animated COVID-19 data visualization dashboard is now available to publishers through Editor and Publisher’s Media Virus Watch, an online resource developed to bring news publishers the latest news, best practices and data on the coronavirus pandemic. 

Infragistics’ interactive visualization tracks all global COVID-19 infections and deaths, daily and by country, since January 30, 2020. Powered by global data sources, including Johns Hopkins University, the U.S. CDC and the World Health Organization (WHO), viewers can click on any of the 223 countries on the dashboard to see the total deaths or infections on a specific day. It also allows users to track trends in a single country or across countries over time. 

Currently, the majority of U.S. news outlets are laser-focused on COVID-19 rates in the U.S. By expanding the data set to encompass worldwide COVID-19 statistics, Americans can get an informed perspective about the country’s progress relative to the rest of the world. Infragistics designed the dynamic dashboard with Indigo.Design and Ignite UI for React, leveraging timely data from CSSEGISandData/COVID-19 to showcase the power of using data to drive decisions.

“This new, engaging COVID-19 dashboard created with Infragistics solutions is an especially informative data asset for newspapers and other news organizations that are covering the coronavirus public health crisis,” says Mike Blinder, publisher, Editor & Publisher. “We are grateful to Infragistics for providing us with an essential tool in our mission to strengthen the support we provide to news organizations.”

“We recognize that we have a responsibility to contribute our technology resources, such as this visualization tool and other expertise, wherever we can to influence the greater good,” said Dean Guida, founder and chief executive officer of Infragistics. “We are pleased to support Editor & Publisher’s Media Virus Watch with our COVID-19 dashboard visualization tool and our door is always open to news organizations seeking business intelligence resources.”

In addition to the partnership with Editor and Publisher, Infragistics’ COVID-19 dashboard is available to any news organization seeking accurate information on the global health crisis. Infragistics also continues to offer its Ignite for Good program, which furnishes open source applications and resources to support those working on COVID-19-related technology projects and provides assistance to small businesses and global customers to accelerate development of new applications that solve problems during the pandemic. Contact Steve Johnston at [email protected] to receive the COVID-19 dashboard or for more information on Ignite for Good.

You can find other Infragistics dashboards and visualizations, including those listed below, here: 

• 
  U.S. Presidential Election Dashboard
  
  : Built in advance of the 2020 election, this visualization takes viewers on an interactive journey of electoral votes dating back to the 1940 race between Franklin D. Roosevelt (449 votes) and Wendell Willkie (82 votes).
• 
  Earthquake
  : This application plots the locations of recent seismic activity and can filter the information about earthquakes based on their region, location, and magnitude.
• 
  Emergency Room
  : Designed for mobile tablet devices, this dashboard displays patients’ vital signs, medical tests and medical orders.
• 
  Marketing
  : Get ready to see your business statistics in a whole new way with this dashboard analyzing spend vs. budget, spend by territory, conversions by campaign and more.
• 
  Predictive Analytics with Reveal
  : Perform a variety of advanced analytics and statistical functions with Infragistics’ new business intelligence tool.

About Infragistics

Infragistics provides the world’s largest enterprises with tools and solutions to accelerate application design and development, and foster team collaboration. More than two million developers worldwide use Infragistics’ enterprise-ready UX and UI toolkits to rapidly prototype and build high-performing applications for the cloud, web, mobile and desktop. Infragistics’ Reveal reimagines what business users can achieve with self-service business intelligence visualization, while its newest application, Indigo.Design, introduces design-to-code efficiencies during the designer-to-developer handoff.  Infragistics clients represent 100% of the S&P 500, including global software providers who rely on Infragistics when reliability and performance are non-negotiable.

About Editor & Publisher

Editor & Publisher is the authoritative voice of news publishing covering all aspects of the industry from the newsroom to advertising and from audience and digital technology to production operations. E&P traces its roots to 1884, and now provides news and analysis in its monthly print edition, its robust website, editorandpublisher.com, mobile app and frequent podcasts with industry leaders. Since September 2019, it has been owned by the Curated Experiences Group with Mike Blinder as its publisher.

Attachment

• Election dashboard 11-23-20

Toronto, Nov. 24, 2020 (GLOBE NEWSWIRE) — FEI Canada is thrilled to announce the launch of their upcoming Virtual Interchange Conference – “Leading with Resilience.”

FEI Canada’s 2021 Leading with Resilience Virtual Interchange will provide a dynamic program of content and networking to help Canada’s financial executives address the timely conversations of resilience and sustainability.

 “Our Interchange Committee is thrilled to be creating a very special experience for you, delivered in a new environment, a reflection of our changing business climate,” said Jeff Shickele, Chair of the 2021 Interchange.

“FEI Canada’s conferences have garnered an unrivalled reputation in Canada’s finance community for providing industry-leading thought leadership, exceptional attendee networking opportunities and magnificent return on investment for sponsors and exhibitors. This year’s virtual environment may look a little different, but we are enthusiastic about providing the same, stellar production,” said Georgina Blanas, Executive Director at FEI Canada.

With a heavy focus on learning and collaboration, the FEI Canada Virtual Interchange will provide enhanced opportunities within the exhibit hall and networking lounges to stay connected with peers or meet new attendees, participate in thought-provoking round table discussions and stay ahead of the curve. Attendees will acquire best practices and solutions to drive business strategy during and after the COVID-19 pandemic.

Registration is now open for the Interchange. To register, and for all information on the Interchange, including sponsorship opportunities, speakers, sessions and run-times, please head to the Interchange website at www.feicanadaconference.ca.    

For information:

Sponsorship opportunities for the two-day event, please reach out to FEI Canada Sponsorship Manager Brad McCabe at [email protected].

For any questions related to the Interchange, please reach out to FEI Canada Director, Events Rita Plaskett, Director Events at [email protected]. 

About Financial Executives International Canada (FEI Canada)

Financial Executives International Canada (FEI Canada) is the leading voice and informed choice for senior financial executives across the country. With 12 chapters and 1,500+ members, FEI Canada provides professional development, networking opportunities, thought leadership and advocacy services to its members. The association membership consists of senior-level financial executives spanning various industries, functions and disciplines, representing a significant number of Canada’s leading and most influential corporations. For more information, please visit www.feicanada.org or follow us on LinkedIn https://ca.linkedin.com/company/fei-canada and Twitter @FEICanada.

Attachment

• FEI_LeadershipBeyondFinance-xs

PETAH TIKVA, Israel, Nov. 24, 2020 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD), a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX technology, today announced that D-PLEX₁₀₀ has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for the prevention of surgical site infections (SSIs) in patients undergoing elective colorectal surgery.

Breakthrough Therapy Designation is an FDA process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition so patients may have access to therapies through FDA approval as soon as possible. This designation is granted based on preliminary clinical evidence indicating that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.

“The Breakthrough Therapy Designation in the field of anti-infective drugs is rather rare, and further supports the urgency to develop new innovative therapies to prevent SSIs,” said Amir Weisberg, PolyPid’s CEO. “It also reflects on the promising clinical data of D-PLEX₁₀₀ in the prevention of SSIs in complex surgical settings, such as colorectal abdominal surgeries. We are looking forward to working closely with the FDA to make D-PLEX₁₀₀ available to surgeons and patients as quickly as possible. Our ongoing Phase 3 pivotal studies in abdominal surgery – SHIELD I and SHIELD II – are on track.”

The Breakthrough Therapy Designation for D-PLEX₁₀₀ is based on conclusive positive results from a Phase 2 clinical trial evaluating D-PLEX₁₀₀ for the prevention of surgical site infections (SSIs) in abdominal colorectal surgery. The Phase 2 clinical trial was a prospective, multicenter, randomized, controlled two arm study in 201 patients and demonstrated that the local administration of D-PLEX₁₀₀ resulted in a statistically significant decrease in SSIs of 59 percent in the Intent to Treat (ITT) population (p=0.0086), and a decrease of 69 percent in the Per Protocol population (n=179; p=0.0024), as compared to the standard of care alone.

D-PLEX₁₀₀ previously received two Fast Track Designations from the FDA for the prevention of post-abdominal surgery incisional infections and for the prevention of sternal wound infections post-cardiac surgery, as well as two Qualified Infectious Disease Product designations (QIDP’s) in the same indications.

About D-PLEX

₁₀₀

PolyPid’s lead product candidate, D-PLEX₁₀₀, is a novel drug product candidate designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX₁₀₀ into the surgical site, the PLEX technology enables a prolonged and constant release of the broad-spectrum antibiotic doxycycline, resulting in high local concentration of the drug for a period of four weeks for the prevention of SSIs, with additional potential to treat antibiotic-resistant bacteria at the surgical site. D-PLEX₁₀₀ has received two Qualified Infectious Disease Product (QIDP) designations as well as two Fast Track designations from the FDA for the prevention of post-abdominal surgery incisional infection and for the prevention of sternal wound infection post-cardiac surgery.

About PolyPid

PolyPid is a Phase 3 clinical-stage biopharmaceutical company focused on developing targeted, locally administered and prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology. PolyPid’s product candidates are designed to address diseases with high unmet medical needs by pairing PLEX with drugs to deliver them directly to precise sites in the body at predetermined release rates and over durations ranging from several days to several months. PolyPid’s lead product candidate, D-PLEX₁₀₀, is in Phase 3 clinical trials for the prevention of sternal SSIs and abdominal SSIs. PolyPid’s technology and products are based on the inventions and the professional leadership of Dr. Noam Emanuel, the Founder and the Chief Scientific Officer of the company.

For additional company information, visit www.polypid.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, PolyPid is using forward-looking statements in this press release when it discusses the potential of D-PLEX₁₀₀ to prevent SSIs, timing, subject matter and frequency of communications with the FDA, and providing a safe and effective solution for surgeons and their patients as quickly as possible. Because such statements deal with future events and are based on PolyPid’s current expectations, they are subject to various risks and uncertainties. Also, while PolyPid has received Fast Track Designation for D-PLEX₁₀₀ for the prevention of surgical site infections, and Breakthrough Therapy Designation for the prevention of SSIs in colorectal surgery, it cannot guarantee that it will be able to maintain such designation due to reasons within our outside of its control. Actual results, performance or achievements of PolyPid could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in PolyPid’s final prospectus dated June 25, 2020, filed pursuant to Rule 424(b)(4) with the Securities and Exchange Commission (“SEC”), and in any subsequent filings with the SEC. Except as otherwise required by law, PolyPid undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

LOS ANGELES, Nov. 24, 2020 (GLOBE NEWSWIRE) — via InvestorWire – InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of the Stock2Me Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.

Stock2Me Podcasts feature a fascinating array of companies and individuals, many of whom are actively revolutionizing age-old business practices within their respective markets.

Stock2Me’s latest podcast features James Sapirstein, president & CEO of AzurRx BioPharma Inc. (NASDAQ: AZRX).

“AzurRx Bio has been around for five years. … Our main product, MS1819, is being studied in chronic pancreatitis and in the GI effects of cystic fibrosis,” Sapirstein stated in the interview. “The market for this particular product (in chronic pancreatitis, competing against pancreatic enzyme replacement therapy (PERT) is about $1 billion outside of the United States and several hundred million dollars inside the United States. The other market is cystic fibrosis. It’s over a $2 billion market worldwide for PERT.”

AzurRx currently has two ongoing clinical trials for MS1819. The first is a Phase 2 Cystic Fibrosis Combination Trial examining MS1819 in combination with PERT, which is expected to produce topline data in Q2 2021.

The company’s second ongoing trial is a Phase 2b Cystic Fibrosis Option 2 monotherapy trial that is expected to produce topline data in Q1 2021. Describing this study, Sapirstein noted, “This is a crossover design study. We place patients on PERT, the existing standard of care therapy, and we also put another line of patients on our drug. These patients take the drugs for three weeks, then we crossover. These patients are not being studied versus placebo. … We’re actually adding another arm where we can dose escalate, because we enrolled the trial very quickly despite COVID. … Because of that, we decided to get some more data out of this trial with another arm.”

Sapirstein went on to discuss the impacts of COVID-19 on AzurRx. The company made a number of adjustments to its clinical development strategy in an effort to better navigate the pandemic. “I immediately, back in February, told my clinical group that this virus is going to be pretty bad and a lot of countries are going to start shutting down. For our combination trial, we decided to start getting some backups. We called the folks in Europe that were working on our trial and told them to get as many patients as possible,” he said. “We also opened up Poland and Turkey. … It takes several months to get these sites up and running and calibrated, so, on the combination trial, we lost about a month on COVID, but not a significant amount of time.”

“In the United States, we took a very different approach with our Option 2 trial,” Sapirstein continued. “Because these patients don’t need a lot of bloodwork, we decided to sequester these folks in hotels. Obviously, there was a lot of hotel space available. We put that into our protocol; we got it approved by the FDA. … That’s how we were able to do it this quickly.”

Join InvestorBrandNetwork’s Stuart Smith and AzurRx’s James Sapirstein in exploring how AzurRx is working to redefine the standard of care for patients living with cystic fibrosis and chronic pancreatitis.

To catch the entire episode and subscribe for future episodes please visit: https://podcast.stock2me.com

The latest installment of The Stock2Me Podcast continues to reinforce InvestorBrandNetwork’s commitment to the expansion of its robust network of brands, client partners, followers and the growing IBN Podcast Series. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.

To learn more about IBN’s achievements and milestones via a visual timeline visit: https://IBN.fm/TimeLine

About InvestorBrandNetwork

The InvestorBrandNetwork (“IBN”) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.

Through NetworkNewsWire (“NNW”) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.

For more information on IBN, visit https://www.InvestorBrandNetwork.com.

Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]